ClinicalTrials.gg
RecruitingNCT06934239Updated Nov 9, 2026

A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

A Phase 4 interventional study of Artificial intelligence (AI) decision-support tool in Breast Cancer Screening and Artificial Intelligence (AI), sponsored by Jonsson Comprehensive Cancer Center. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Jonsson Comprehensive Cancer Center · Phase 4, Interventional, and Screening

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · Jonsson Comprehensive Cancer Center.

Planned enrollment
Largest of 37
400,000 · median 42
Started
2025
with 1 other
Phase 4
2 of 46
1 open now
Primary completion
2028-03
later than 6 of 10 live
Registered
44th of 46
by date

Among the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center, this one has the largest planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 6 of the 10 other live ones, and was the 44th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare patient-centered outcomes when screening digital breast tomosynthesis (DBT) exams are interpreted with versus without a leading FDA-cleared artificial intelligence (AI) decision-support tool in real-world U.S. settings and to assess patients' and radiologists' perspectives on AI in medicine.

The main question it aims to answer is: Does an FDA-cleared AI decision-support tool for digital tomosynthesis (DBT) improve screening outcomes in real world US clinical settings?

This trial will include all interpreting radiologists and all adult patients undergoing screening mammography at any of the participating breast imaging facilities across 6 regional health systems (University of California, Los Angeles (UCLA), University of California, San Diego (UCSD), University of Washington-Seattle, University of Wisconsin-Madison, Boston Medical Center, and University of Miami) during the trial period.

All screening mammograms at these facilities will be randomized to either intervention (radiologist assisted by an AI decision support tool) versus usual care (radiologist alone) to see if interpreting these mammograms with the AI tool's assistance improves patient screening outcomes.

We are targeting 400,000 screening exams across the participating health systems in this trial.

Read the detailed description

During the RCT the AI support tool will be randomized to be turned on or off (1:1) at the mammography exam level. Patients who return for screening exams in year 2 of recruitment will be randomized again (e.g., they will not retain their prior randomization). Radiologists will not be able to sort exams based on AI availability or AI scores. Randomizing by exam level will ensure that we capture a substantial number of interpretations with vs. without AI for each radiologist, allowing for quantification of the radiologist-level AI learning curve. We are not randomizing at the facility level as some radiologists interpret exams acquired at different facilities on the same day. By randomizing AI at the exam level, we will have the best ability to estimate and adjust for temporal trends in screening outcomes across individual radiologists. Randomization across large regional health systems will be managed independently at each participating site.

Our RCT randomizes screening mammography exams to be interpreted either with or without an AI decision-support tool. As a result, radiologists cannot be blinded to study arm during screening mammography interpretation. However, interpreting radiologists and facility staff (e.g., those scheduling the exams) will not know in advance which patients will be randomized to the AI tool. Randomization occurs within minutes after the breast imaging acquisition (i.e., when the mammography technologist captures the images) by an automated system that was developed by a third-party AI platform and successfully piloted at UCLA. Thus, the AI data (or lack thereof) is embedded within the mammogram before the radiologist opens the exam, preventing any option to "add AI" to an exam randomized to be interpreted without AI. Radiologists will be aware of AI availability only at the time of interpretation, as AI information will appear upon opening the exam (e.g., the AI information pops up with the exam images).

03

Conditions studied

  • Breast Cancer Screening
  • Artificial Intelligence (AI)

Browse trials for

Keywords

  • Breast cancer screening
  • Artificial intelligence (AI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

This trial will include all radiologists interpreting screening mammography and all adult patients undergoing screening mammography at any of the participating breast imaging facilities across 6 regional health systems (UCLA, UC San Diego, University of Washington-Seattle, University of Wisconsin-Madison, Boston Medical Center, and University of Miami) during the trial period. Individuals must meet the following eligiblity criteria.

Inclusion criteria

Inclusion Criteria:

  1. Be at least 18 years of age or older
  2. Receive a screening mammogram at one of the participating breast imaging facilities OR be a radiologist who interprets screening mammograms at one of the participating breast imaging facilities.

Exclusion criteria

Exclusion Criteria:

1. Patients who have opted out of all research at the health system

05

Study design

Phase
Phase 4
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
400,000 participants (estimated)

Study arms

  • Active comparator
    Intervention (radiologist assisted by AI)

    3D screening exams randomized to this arm will be interpreted by the radiologist assisted by the AI decision-support tool (i.e., intervention).

    Device: Artificial intelligence (AI) decision-support tool

  • No intervention
    Standard care (radiologist alone)

    3D screening exams randomized to this arm will be interpreted in accordance with standard care (i.e., interpreted by the radiologist alone, without an AI decision-support tool's assistance).

Interventions

  • DeviceArtificial intelligence (AI) decision-support tool

    The intervention is an AI decision-support tool to help radiologists interpret 3D screening mammograms. For exams randomized to this intervention arm, the first image displayed to the radiologist upon opening an exam on the viewing station will be a one-page, standardized AI report showing the overall exam risk (elevated, intermediate, or low), image region markings, lesion scores from 1-100 (100 being the highest suspicion), bounding boxes, and relevant slice locations for 3D exams. Radiologists can toggle markings on/off and retain full control over the final interpretation of the exam as positive or negative (i.e., they can choose to ignore the AI information). Randomization occurs 1:1 at the exam level via automated code at image acquisition. Returning patients in year two will be re-randomized. Radiologists cannot filter their exam lists by AI availability or risk, and randomization will be independently managed at each participating health system.

06

What researchers measure

Primary outcomes

  1. Cancer detection rate

    Number of screening exams recommended for breast biopsy (final Breast Imaging- Reporting and Data System \[BI-RADS\] assessment of 4 or 5) resulting in detected cancer, per 1,000 screening exams

    Time frame: Cancer diagnosed within 90 days of positive study entry screening mammogram

  2. Recall rate

    Number of screening exams recalled for diagnostic work-up (initial BI-RADS assessment of 0, 3, 4, or 5), per 1,000 screening exams

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Interval cancer rate (i.e., false-negative rate)

    Number of screening exams with a negative assessment (final BI-RADS assessment of 1 or 2) and breast cancer diagnosed within 1 year, per 1,000 screening exams

    Time frame: Cancer diagnosed within 365 days of a negative study entry screening mammogram

  2. False positive recall rate

    Proportion of screening exams recalled for additional imaging (final BI-RADS assessment of 1, 2, or 3), with no breast cancer diagnosed within 1 year

    Time frame: No cancer diagnosed within 365 days of a positive study entry screening mammogram

  3. False positive short-interval follow-up recommendation rate

    Proportion of screening exams recalled for short-interval follow-up (final BI-RADS assessment of 3) with no breast cancer diagnosed within 1 year

    Time frame: No cancer diagnosed within 365 days of a positive study entry screening mammogram

  4. False positive biopsy recommendation rate

    Proportion of screening exams recalled for breast biopsy (final BI-RADS assessment of 4 or 5) with no breast cancer diagnosed within 1 year

    Time frame: No cancer diagnosed within 365 days of a positive study entry screening mammogram

  5. Trust and confidence in AI

    Trust and confidence in AI gathered from focus group and survey data

    Time frame: Years 1,2 and Years 4,5

  6. Efficiency metrics (only for the UCLA site)

    Interpretation time required for radiologists to interpret each mammogram with versus without AI. Delivery time, using time stamp data from exam acquisition to delivery of results to patients (aka turnaround time).

    Time frame: Through study completion, an average of 1 year

07

Study locations

6 of 6 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — A de-identified dataset from this study will be deposited in the Patient-Centered Outcomes Data Repository (PCODR) housed at the Inter-university Consortium for Political and Social Research (ICPSR) at the University of Michigan, in compliance with PCORI's Policy on Data Management and Data Sharing.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.

Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 28 months is below that.

Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 18, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06934239
Responsible party
Sponsor
First posted
Apr 18, 2025
Start date
Oct 15, 2025
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Michelle L'Hommedieu, PhD
Contact
mlhommedieu@mednet.ucla.edu
(310) 592-9454
Joann G Elmore, MD, MPH
principal investigator · University of California, Los Angeles
Diana Miglioretti, PhD
principal investigator · University of California, Davis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion